Johannes Mohm

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Peter Borchmann, Annette Plütschow, Carsten Kobe et al. · The Lancet Oncology · 2021 · 168 citations

Medicine, Oncology, Radiology +13

Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life‐threatening vincristine neurotoxicity

Ralph Naumann, Johannes Mohm, Ulrike Reuner et al. · British Journal of Haematology · 2001 · 58 citations · Full text

Medicine, Neurology, Oncology +17

Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial

Arndt Vogel, Anna Saborowski, Patrick Wenzel et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Nadia Harbeck, Peter A. Fasching, Rachel Wuerstlein et al. · Annals of Oncology · 2023 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML

Thomas Fischer, Andreas Neubauer, Johannes Mohm et al. · Bone Marrow Transplantation · 1998 · 23 citations

Medicine, Oncology, Chemotherapy +7